詞庫查詢
查詢 Elsevier TF-IDF 關鍵詞（16,935 詞）與 THU 中文擴充詞庫。想知道自己的研究會命中哪些規則？先查這裡。
Elsevier TF-IDF 詞 16,935 筆
| SDG | 目標 | 詞 | 集合內文獻 | Scopus 文獻 | 佔比 | TF-IDF |
|---|---|---|---|---|---|---|
| 3 | 良好健康與福祉 | stroke units |
1,512 | 1,623 | 93% | 19.23 |
| 3 | 良好健康與福祉 | experimental stroke |
1,690 | 1,832 | 92% | 19.23 |
| 3 | 良好健康與福祉 | 5-year overall survival rate |
3,913 | 4,208 | 93% | 19.23 |
| 3 | 良好健康與福祉 | ipilimumab |
4,289 | 4,572 | 94% | 19.23 |
| 3 | 良好健康與福祉 | oncogenic pathway |
2,535 | 2,785 | 91% | 19.23 |
| 3 | 良好健康與福祉 | mtct |
3,183 | 3,473 | 92% | 19.23 |
| 3 | 良好健康與福祉 | human pancreatic cancer cell |
2,545 | 2,796 | 91% | 19.23 |
| 3 | 良好健康與福祉 | glargine |
2,992 | 3,274 | 91% | 19.23 |
| 3 | 良好健康與福祉 | concurrent chemotherapy |
3,287 | 3,581 | 92% | 19.23 |
| 3 | 良好健康與福祉 | anti-pd-l1 |
2,411 | 2,650 | 91% | 19.23 |
| 3 | 良好健康與福祉 | cutaneous squamous cell carcinoma |
3,156 | 3,446 | 92% | 19.23 |
| 3 | 良好健康與福祉 | clinicopathological variable |
2,681 | 2,944 | 91% | 19.23 |
| 3 | 良好健康與福祉 | lung cancer (lc) |
1,536 | 1,652 | 93% | 19.23 |
| 3 | 良好健康與福祉 | asthma prevalence |
1,784 | 1,942 | 92% | 19.23 |
| 3 | 良好健康與福祉 | clinicopathological variables |
2,641 | 2,901 | 91% | 19.23 |
| 3 | 良好健康與福祉 | total mesorectal excision (tme) |
1,385 | 1,473 | 94% | 19.23 |
| 3 | 良好健康與福祉 | virologic response |
5,129 | 5,355 | 96% | 19.23 |
| 3 | 良好健康與福祉 | raltegravir |
1,880 | 2,053 | 92% | 19.23 |
| 3 | 良好健康與福祉 | esophageal cancer patients |
2,623 | 2,882 | 91% | 19.23 |
| 3 | 良好健康與福祉 | lymph node staging |
1,523 | 1,637 | 93% | 19.23 |
| 3 | 良好健康與福祉 | cause-specific survival |
2,148 | 2,358 | 91% | 19.23 |
| 3 | 良好健康與福祉 | uterine cervical neoplasms |
1,556 | 1,676 | 93% | 19.23 |
| 3 | 良好健康與福祉 | active cancer |
1,918 | 2,097 | 91% | 19.23 |
| 3 | 良好健康與福祉 | stomach neoplasms |
3,733 | 4,033 | 93% | 19.23 |
| 3 | 良好健康與福祉 | gynecological cancers |
1,706 | 1,852 | 92% | 19.23 |
| 3 | 良好健康與福祉 | cancer diagnosis and therapy |
1,286 | 1,355 | 95% | 19.23 |
| 3 | 良好健康與福祉 | egfr-mutant |
1,548 | 1,667 | 93% | 19.23 |
| 3 | 良好健康與福祉 | hnscc cell lines |
1,206 | 1,259 | 96% | 19.23 |
| 3 | 良好健康與福祉 | imaging prostate cancer |
1,172 | 1,218 | 96% | 19.23 |
| 3 | 良好健康與福祉 | active surveillance (as) |
1,143 | 1,183 | 97% | 19.23 |
| 3 | 良好健康與福祉 | ear cancer |
1,709 | 1,856 | 92% | 19.23 |
| 3 | 良好健康與福祉 | hiv intervention |
1,386 | 1,475 | 94% | 19.23 |
| 3 | 良好健康與福祉 | novel anticancer agent |
1,391 | 1,481 | 94% | 19.23 |
| 3 | 良好健康與福祉 | advanced/metastatic |
1,152 | 1,194 | 96% | 19.23 |
| 3 | 良好健康與福祉 | clinically significant prostate cancer |
1,269 | 1,335 | 95% | 19.23 |
| 3 | 良好健康與福祉 | diabetes self-care |
1,380 | 1,468 | 94% | 19.23 |
| 3 | 良好健康與福祉 | palliative chemotherapy |
3,115 | 3,406 | 91% | 19.23 |
| 3 | 良好健康與福祉 | egfr-tk |
4,411 | 4,693 | 94% | 19.23 |
| 3 | 良好健康與福祉 | human cervical cancer |
3,138 | 3,430 | 91% | 19.23 |
| 3 | 良好健康與福祉 | immunogenic cell death |
2,279 | 2,506 | 91% | 19.23 |
| 3 | 良好健康與福祉 | vemurafenib |
2,227 | 2,448 | 91% | 19.23 |
| 3 | 良好健康與福祉 | du145 cells |
1,706 | 1,853 | 92% | 19.23 |
| 3 | 良好健康與福祉 | sh-sy5y neuroblastoma cells |
1,506 | 1,618 | 93% | 19.23 |
| 3 | 良好健康與福祉 | plhiv |
2,322 | 2,554 | 91% | 19.23 |
| 3 | 良好健康與福祉 | immune-related adverse events (iraes) |
1,646 | 1,783 | 92% | 19.23 |
| 3 | 良好健康與福祉 | driver distraction |
1,566 | 1,689 | 93% | 19.23 |
| 3 | 良好健康與福祉 | microsatellite instability (msi) |
4,088 | 4,384 | 93% | 19.23 |
| 3 | 良好健康與福祉 | du-145 |
2,103 | 2,309 | 91% | 19.23 |
| 3 | 良好健康與福祉 | obesity in children |
3,257 | 3,554 | 92% | 19.23 |
| 3 | 良好健康與福祉 | circulating tumor dna |
3,421 | 3,722 | 92% | 19.23 |